In a research report released this morning, Maxim Group analyst Jason Kolbert maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) with a price …
J.P.
Maxim Group analyst Jason Kolbert maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) with a price target of $127, as the company’s hepatitis C drugs, …
Gilead Sciences (NASDAQ: GILD) took a hit a few weeks ago when healthcare provider Express Scripts (NASDAQ: ESRX) chose AbbVie’s (NYSE: ABBV) hepatitis C drug over …
In a research report sent to investors a short while ago, J.P.
In a research report sent to investors today, Cowen analyst Phil Nadeau maintained an Outperform rating on Gilead Sciences (NASDAQ:GILD) with a price …
In a research report published today, Deutsche Bank analyst Robyn Karnauskas maintained a Buy rating on Gilead Sciences (NASDAQ:GILD), but reduced her price …
William Blair analyst John Sonnier is out with a research note on Gilead Sciences (NASDAQ:GILD), reiterating an Outperform rating, following the announcement from Express Scripts (NASDAQ:ESRX) …
Maxim’s healthcare analyst Jason Kolbert joined Piper Jaffray today, commenting on Gilead Sciences (NASDAQ:GILD), following the news that Express Scripps (NASDAQ:ESRX) will only cover AbbVie’s (NYSE:ABBV) HCV …
